Literature DB >> 2557027

Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo).

G Belvedere1, A Suarato, C Geroni, F C Giuliani, M D'Incalci.   

Abstract

Formation of DNA single strand breaks (SSB) was assayed by alkaline elution in LoVo cells treated with doxorubicin, daunorubicin and six derivatives of these drugs modified either in the chromophore or the sugar. Seven compounds showed a biphasic relationship (initial increase and then a decrease) for the formation of DNA-SSB over the concentration range 0.05-10 micrograms/ml. At a drug concentration in the range causing an increase of DNA damage very fast repair of DNA-SSB was observed for 4'-deoxydoxorubicin and 4-demethoxydaunorubicin; the kinetics of DNA-SSB investigated after drug removal at a drug concentration reducing DNA-SSB showed a time dependent increase of DNA damage for both drugs although with different patterns. 4'-Deoxydoxorubicin reduced the effect of radiations on the rate of elution of DNA in a way resembling the formation of DNA interstrand cross links (ISC) at concentrations at which DNA-SSB were reduced. DNA-ISC were not produced by chemical reactions occurring during sample processing for alkaline elution and this derivative was not metabolized by LoVo cells. The IC50 of the anthracyclines were on a several log range, though for most of the derivatives the cytotoxicity curve showed a plateau at growth inhibition of about 15-30% at increasing intracellular drug levels. A relationship between DNA damage and cytotoxicity was observed only in a very small range of DNA-SSB. It is likely that the different effects of these anthracyclines on the formation of DNA-SSB depend on a qualitatively different interaction between drug-DNA and topoisomerase II when the drug concentration is raised.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557027     DOI: 10.1016/0006-2952(89)90577-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.

Authors:  L Capolongo; G Belvedere; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.

Authors:  F Gieseler; H Biersack; T Brieden; J Manderscheid; V Nüssler
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

4.  Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.

Authors:  M Limonta; A Biondi; G Giudici; G Specchia; C Catapano; G Masera; T Barbui; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.

Authors:  R Danesi; N Bernardini; C Agen; M Costa; L Zaccaro; D Pieracci; G Malvaldi; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.